167 related articles for article (PubMed ID: 26748711)
21. CDK12: an emerging therapeutic target for cancer.
Lui GYL; Grandori C; Kemp CJ
J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286
[TBL] [Abstract][Full Text] [Related]
22. EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.
Iniguez AB; Stolte B; Wang EJ; Conway AS; Alexe G; Dharia NV; Kwiatkowski N; Zhang T; Abraham BJ; Mora J; Kalev P; Leggett A; Chowdhury D; Benes CH; Young RA; Gray NS; Stegmaier K
Cancer Cell; 2018 Feb; 33(2):202-216.e6. PubMed ID: 29358035
[TBL] [Abstract][Full Text] [Related]
23. CDK13 RNA Over-Editing Mediated by ADAR1 Associates with Poor Prognosis of Hepatocellular Carcinoma Patients.
Dong X; Chen G; Cai Z; Li Z; Qiu L; Xu H; Yuan Y; Liu XL; Liu J
Cell Physiol Biochem; 2018; 47(6):2602-2612. PubMed ID: 29996118
[TBL] [Abstract][Full Text] [Related]
24. Phenotypic and molecular characterisation of CDK13-related congenital heart defects, dysmorphic facial features and intellectual developmental disorders.
Bostwick BL; McLean S; Posey JE; Streff HE; Gripp KW; Blesson A; Powell-Hamilton N; Tusi J; Stevenson DA; Farrelly E; Hudgins L; Yang Y; Xia F; Wang X; Liu P; Walkiewicz M; McGuire M; Grange DK; Andrews MV; Hummel M; Madan-Khetarpal S; Infante E; Coban-Akdemir Z; Miszalski-Jamka K; Jefferies JL; ; Rosenfeld JA; Emrick L; Nugent KM; Lupski JR; Belmont JW; Lee B; Lalani SR
Genome Med; 2017 Aug; 9(1):73. PubMed ID: 28807008
[TBL] [Abstract][Full Text] [Related]
25. The emerging roles of CDK12 in tumorigenesis.
Paculová H; Kohoutek J
Cell Div; 2017; 12():7. PubMed ID: 29090014
[TBL] [Abstract][Full Text] [Related]
26. The emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE.
Paparidis NF; Durvale MC; Canduri F
Mol Biosyst; 2017 Jan; 13(2):246-276. PubMed ID: 27833949
[TBL] [Abstract][Full Text] [Related]
27. Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.
Greenleaf AL
Transcription; 2019 Apr; 10(2):91-110. PubMed ID: 30319007
[TBL] [Abstract][Full Text] [Related]
28. Dephosphorylating eukaryotic RNA polymerase II.
Mayfield JE; Burkholder NT; Zhang YJ
Biochim Biophys Acta; 2016 Apr; 1864(4):372-87. PubMed ID: 26779935
[TBL] [Abstract][Full Text] [Related]
29. CDK13 cooperates with CDK12 to control global RNA polymerase II processivity.
Fan Z; Devlin JR; Hogg SJ; Doyle MA; Harrison PF; Todorovski I; Cluse LA; Knight DA; Sandow JJ; Gregory G; Fox A; Beilharz TH; Kwiatkowski N; Scott NE; Vidakovic AT; Kelly GP; Svejstrup JQ; Geyer M; Gray NS; Vervoort SJ; Johnstone RW
Sci Adv; 2020 May; 6(18):. PubMed ID: 32917631
[TBL] [Abstract][Full Text] [Related]
30. CDK12 regulates DNA repair genes by suppressing intronic polyadenylation.
Dubbury SJ; Boutz PL; Sharp PA
Nature; 2018 Dec; 564(7734):141-145. PubMed ID: 30487607
[TBL] [Abstract][Full Text] [Related]
31. CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression.
Mitra P; Yang RM; Sutton J; Ramsay RG; Gonda TJ
Oncotarget; 2016 Feb; 7(8):9069-83. PubMed ID: 26812885
[TBL] [Abstract][Full Text] [Related]
32. Dysregulated expression of microRNAs and mRNAs in myocardial infarction.
Wang Y; Pan X; Fan Y; Hu X; Liu X; Xiang M; Wang J
Am J Transl Res; 2015; 7(11):2291-304. PubMed ID: 26807177
[TBL] [Abstract][Full Text] [Related]
33. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.
Zeng M; Kwiatkowski NP; Zhang T; Nabet B; Xu M; Liang Y; Quan C; Wang J; Hao M; Palakurthi S; Zhou S; Zeng Q; Kirschmeier PT; Meghani K; Leggett AL; Qi J; Shapiro GI; Liu JF; Matulonis UA; Lin CY; Konstantinopoulos PA; Gray NS
Elife; 2018 Nov; 7():. PubMed ID: 30422115
[TBL] [Abstract][Full Text] [Related]
34. Genome-wide association study identifies novel recessive genetic variants for high TGs in an Arab population.
Hebbar P; Nizam R; Melhem M; Alkayal F; Elkum N; John SE; Tuomilehto J; Alsmadi O; Thanaraj TA
J Lipid Res; 2018 Oct; 59(10):1951-1966. PubMed ID: 30108155
[TBL] [Abstract][Full Text] [Related]
35. Corrigendum: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.
Cayrol F; Praditsuktavorn P; Fernando TM; Kwiatkowski N; Marullo R; Calvo-Vidal MN; Phillip J; Pera B; Yang SN; Takpradit K; Roman L; Gaudiano M; Crescenzo R; Ruan J; Inghirami G; Zhang T; Cremaschi G; Gray NS; Cerchietti L
Nat Commun; 2017 Feb; 8():14747. PubMed ID: 28218232
[No Abstract] [Full Text] [Related]
36. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
Quereda V; Bayle S; Vena F; Frydman SM; Monastyrskyi A; Roush WR; Duckett DR
Cancer Cell; 2019 Nov; 36(5):545-558.e7. PubMed ID: 31668947
[TBL] [Abstract][Full Text] [Related]
37. CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.
Choi HJ; Jin S; Cho H; Won HY; An HW; Jeong GY; Park YU; Kim HY; Park MK; Son T; Min KW; Jang KS; Oh YH; Lee JY; Kong G
EMBO Rep; 2019 Oct; 20(10):e48058. PubMed ID: 31468695
[TBL] [Abstract][Full Text] [Related]
38. Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V.
Zhang X; Nguyen KD; Rudnick PA; Roper N; Kawaler E; Maity TK; Awasthi S; Gao S; Biswas R; Venugopalan A; Cultraro CM; Fenyö D; Guha U
Mol Cell Proteomics; 2019 Apr; 18(4):622-641. PubMed ID: 30617155
[TBL] [Abstract][Full Text] [Related]
39. Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery.
Liu H; Liu K; Dong Z
Cancer Res; 2021 Jan; 81(1):18-26. PubMed ID: 32958547
[TBL] [Abstract][Full Text] [Related]
40. Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.
Chou J; Quigley DA; Robinson TM; Feng FY; Ashworth A
Cancer Discov; 2020 Mar; 10(3):351-370. PubMed ID: 32071145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
